IDEAYA Biosciences Inc
IDYA35.200USD
-0.480-1.35%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.09BMarket Cap
LossP/E TTM
More Details of IDEAYA Biosciences Inc Company
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
IDEAYA Biosciences Inc Info
Ticker SymbolIDYA
Company nameIDEAYA Biosciences Inc
IPO dateMay 23, 2019
CEOHata (Yujiro S)
Number of employees131
Security typeOrdinary Share
Fiscal year-endMay 23
Address7000 Shoreline Ct, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504436209
Websitehttps://www.ideayabio.com/
Ticker SymbolIDYA
IPO dateMay 23, 2019
CEOHata (Yujiro S)
Company Executives of IDEAYA Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
7.00M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.59%
Other
57.38%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.59%
Other
57.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.76%
Investment Advisor/Hedge Fund
32.44%
Hedge Fund
19.91%
Research Firm
3.93%
Venture Capital
3.62%
Pension Fund
1.00%
Individual Investor
0.90%
Bank and Trust
0.43%
Insurance Company
0.07%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.14M
14.99%
+7.07K
+0.05%
Jun 30, 2025
Capital Research Global Investors
6.55M
7.48%
+3.82M
+139.59%
Jun 30, 2025
Janus Henderson Investors
6.21M
7.08%
-195.54K
-3.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.67M
7.61%
-480.56K
-6.72%
Jun 30, 2025
The Vanguard Group, Inc.
4.92M
5.62%
-152.94K
-3.01%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-140.66K
-2.95%
Jun 30, 2025
Point72 Asset Management, L.P.
5.03M
5.74%
+4.89M
+3488.42%
Jun 30, 2025
Baker Bros. Advisors LP
2.12M
2.42%
+1.06M
+99.48%
Jun 30, 2025
State Street Investment Management (US)
3.39M
3.86%
-60.44K
-1.75%
Jun 30, 2025
Adage Capital Management, L.P.
1.24M
1.41%
+50.00K
+4.21%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
View more
Tema Oncology ETF
Proportion3.49%
ALPS Medical Breakthroughs ETF
Proportion1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.83%
State Street SPDR S&P Biotech ETF
Proportion0.72%
First Trust Innovation Leaders ETF
Proportion0.7%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.45%
ProShares Ultra Nasdaq Biotechnology
Proportion0.38%
Avantis US Small Cap Equity ETF
Proportion0.29%
Invesco Nasdaq Biotechnology ETF
Proportion0.27%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of IDEAYA Biosciences Inc?
The top five shareholders of IDEAYA Biosciences Inc are:
Fidelity Management & Research Company LLC holds 13.14M shares, accounting for 14.99% of the total shares.
Capital Research Global Investors holds 6.55M shares, accounting for 7.48% of the total shares.
Janus Henderson Investors holds 6.21M shares, accounting for 7.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.67M shares, accounting for 7.61% of the total shares.
The Vanguard Group, Inc. holds 4.92M shares, accounting for 5.62% of the total shares.
Fidelity Management & Research Company LLC holds 13.14M shares, accounting for 14.99% of the total shares.
Capital Research Global Investors holds 6.55M shares, accounting for 7.48% of the total shares.
Janus Henderson Investors holds 6.21M shares, accounting for 7.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.67M shares, accounting for 7.61% of the total shares.
The Vanguard Group, Inc. holds 4.92M shares, accounting for 5.62% of the total shares.
What are the top three shareholder types of IDEAYA Biosciences Inc?
The top three shareholder types of IDEAYA Biosciences Inc are:
Fidelity Management & Research Company LLC
Capital Research Global Investors
Janus Henderson Investors
Fidelity Management & Research Company LLC
Capital Research Global Investors
Janus Henderson Investors
How many institutions hold shares of IDEAYA Biosciences Inc (IDYA)?
As of 2025Q3, 460 institutions hold shares of IDEAYA Biosciences Inc, with a combined market value of approximately 105.73M, accounting for 120.62% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 4.57%.
What is the biggest source of revenue for IDEAYA Biosciences Inc?
In FY2024, the WRN business generated the highest revenue for IDEAYA Biosciences Inc, amounting to 7.00M and accounting for --% of total revenue.
